[go: up one dir, main page]

AR078884A1 - Antagonistas del receptor crth2 basados en indol - Google Patents

Antagonistas del receptor crth2 basados en indol

Info

Publication number
AR078884A1
AR078884A1 ARP100104065A ARP100104065A AR078884A1 AR 078884 A1 AR078884 A1 AR 078884A1 AR P100104065 A ARP100104065 A AR P100104065A AR P100104065 A ARP100104065 A AR P100104065A AR 078884 A1 AR078884 A1 AR 078884A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heteroaryl
cycloalkyl
heterocycloalkyl
Prior art date
Application number
ARP100104065A
Other languages
English (en)
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of AR078884A1 publication Critical patent/AR078884A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Como antagonistas de los receptores CRTH2. También se desvelan composiciones farmacéuticas que contienen compuestos de Formula (1) y el uso de compuestos de Formula (1) para tratar enfermedades o trastornos que son sensibles a la inhibicion de la union de ligandos endogenos al receptor CRTH2. Reivindicacion 1: Un compuesto de Formula (1): o una sal farmacéuticamente aceptable del mismo; en la que: - - - - - es un enlace sencillo o un doble enlace o está ausente; cada uno de R1 y R2 es independientemente H, halogeno, OR6, SO2R7, NR8R9, o alquilo; en los que R6 es H o alquilo; R7 es alquilo; cada uno de R8 y R9 es independientemente H, COCH3 o alquilo; R3 es hidroxi, alquilo, alquenilo, alquinilo, arilo, heteroarilo, cicloalquilo o heterocicloalquilo, en los que cada alquilo, alquenilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo está opcionalmente sustituido con Ra; siendo Ra alquilo, arilo, heteroarilo, cicloalquilo, alcoxi, fenoxi, halogeno, hidroxi, amino, mono- o di-alquilamino, nitro, haloalquilo, haloalcoxi, halofenoxi, CO, carboxamida, sulfonamida o SO2Me, en los que cada alquilo, arilo, heteroarilo está opcionalmente sustituido adicionalmente con H, alquilo, arilo, alcoxi, fenoxi, halogeno, hidroxi, haloalquilo, haloalcoxi, halofenoxi o SO2Me; R4 es H o alquilo; R5 es CR10R11COOR12, CR10R11CR13NR14R15, COR17, CR10R11CN, CR10R11CR19; en los que cada uno de R10 y R11 es independientemente H o alquilo; R es H o alquilo; R13 es O; cada uno de R14 y R15 es independientemente H, COCH3, SO2R16, alquilo, arilo, heteroarilo, cicloalquilo o heterocicloalquilo; en los que R16 es H, alquilo, arilo, heteroarilo, cicloalquilo o heterocicloalquilo; R17 es alquilo, arilo, heteroarilo, estando cada uno de ellos opcionalmente sustituido con -OH u OR18; en los que R18 es alquilo; R19 es alquilo; arilo, heteroarilo o alquilo opcionalmente sustituido con -OH; X es CH o N; y n es 0 o 1.
ARP100104065A 2009-11-04 2010-11-03 Antagonistas del receptor crth2 basados en indol AR078884A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25797509P 2009-11-04 2009-11-04

Publications (1)

Publication Number Publication Date
AR078884A1 true AR078884A1 (es) 2011-12-07

Family

ID=43413493

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104065A AR078884A1 (es) 2009-11-04 2010-11-03 Antagonistas del receptor crth2 basados en indol

Country Status (5)

Country Link
US (1) US20110105509A1 (es)
AR (1) AR078884A1 (es)
TW (1) TW201127823A (es)
UY (1) UY32996A (es)
WO (1) WO2011055270A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
BR112013000254A2 (pt) 2010-07-05 2016-05-24 Actelion Pharmaceuticals Ltd derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
US9044451B2 (en) 2010-07-19 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
SG193902A1 (en) 2011-04-14 2013-11-29 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2548863A1 (en) * 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013093842A1 (en) 2011-12-21 2013-06-27 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
CN104428305A (zh) 2012-07-05 2015-03-18 埃科特莱茵药品有限公司 1-苯基-取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
WO2014026329A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014078573A2 (en) 2012-11-16 2014-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tocopherol and tocopheryl quinone derivatives as correctors of lysosomal storage disorders
MX365950B (es) * 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
GB201322273D0 (en) * 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
UA117780C2 (uk) 2014-03-17 2018-09-25 Ідорсія Фармасьютікалз Лтд Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
TW201620909A (zh) 2014-03-18 2016-06-16 艾克泰聯製藥有限公司 氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途
CA2943363A1 (en) * 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
CN106467495A (zh) * 2015-08-19 2017-03-01 中国科学院上海药物研究所 哒嗪酮类化合物、其制备方法、药物组合物及用途
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
MX379014B (es) 2015-09-15 2025-03-10 Idorsia Pharmaceuticals Ltd Formas cristalinas.
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
JP7012822B2 (ja) * 2017-08-10 2022-02-14 中国科学院上海薬物研究所 フタラジノン系化合物、その製造方法、医薬組成物及びその使用
SI3746441T1 (sl) * 2018-02-02 2023-08-31 Genentech Inc. Farmacevtska spojina, njene soli, njene formulacije ter postopki izdelave in uporabe le-teh
CN110143945B (zh) * 2018-02-14 2021-01-01 新发药业有限公司 一种4-取代基甲基-1-(2h)酞嗪酮的简便制备方法
CN112125881B (zh) * 2019-06-25 2023-03-28 中国科学院上海药物研究所 4-吡啶取代酞嗪酮类化合物、其制备方法、药物组合物及用途
CN112679469B (zh) * 2020-12-29 2021-11-16 山东研峰新材料科技有限公司 一种四氢异喹啉类衍生物、制备方法及应用
CN114835677B (zh) * 2021-02-02 2025-09-26 广东东阳光药业股份有限公司 吲哚衍生物的盐及其用途
CN114835678A (zh) * 2021-02-02 2022-08-02 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
CN114989136A (zh) * 2021-02-02 2022-09-02 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
WO2023086799A1 (en) * 2021-11-09 2023-05-19 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
KR20070089908A (ko) * 2004-09-21 2007-09-04 아더시스 인코포레이티드 Ｃｒｔｈ２ 수용체 길항작용을 나타내는 인돌 아세트산 및이의 용도

Also Published As

Publication number Publication date
WO2011055270A1 (en) 2011-05-12
US20110105509A1 (en) 2011-05-05
TW201127823A (en) 2011-08-16
UY32996A (es) 2011-06-30

Similar Documents

Publication Publication Date Title
AR078884A1 (es) Antagonistas del receptor crth2 basados en indol
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
MA34078B1 (fr) Derives d'arylethynyle
AR062965A1 (es) Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos
CO6251248A2 (es) Compuestos de tiazolopiridina como moduladores de sirtuina
AR062360A1 (es) Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
AR076460A1 (es) Antagonistas del receptor cxcr3
EA200901379A1 (ru) Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
CO6260076A2 (es) Derivados de uracilo o timina para el tratamiento de la hepatitis c
AR059955A1 (es) Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide
AR072224A1 (es) Derivados de pirimidona sustituidos
MX379353B (es) Compuesto de piperidina tipo quinoxalina sustituida y uso de los mismos.
TNSN08311A1 (en) Indole sulfonamide modulators of progesterone receptors
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
PE20170084A1 (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4-9(10)-dien-11-arilo como antagonistas de progesterona y procedimientos para su preparacion
AR079550A1 (es) Derivados de pirazol
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
PE20211070A1 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität

Legal Events

Date Code Title Description
FA Abandonment or withdrawal